Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
objective response
Description:
An objectively assessed change in a disease or condition following treatment, often measured by tumor shrinkage or other clinical criteria.
Related topics:
Cancer Immunotherapy and Biomarkers (9%),
Hepatocellular Carcinoma Treatment and Prognosis (7%)
OpenAlex ID:
keywords/objective-response
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008
·
E.A. Eisenhauer
, P. Therasse
, et al.
·
European Journal of Cancer
·
31,601
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2001
·
Dennis J. Slamon
, Brian Leyland-Jones
, et al.
·
New England Journal of Medicine
·
12,612
PDF
Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer
2004
·
Daniel P. Petrylak
, Catherine M. Tangen
, et al.
·
New England Journal of Medicine
·
3,888
PDF
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
2015
·
Jeffrey S Weber
, Sandra P D'Angelo
, et al.
·
The Lancet Oncology
·
2,899
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
2018
·
Andrew X Zhu
, Richard S Finn
, et al.
·
The Lancet Oncology
·
2,655
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
2010
·
Wendy De Roock
, Bart Claes
, et al.
·
The Lancet Oncology
·
2,358
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
2015
·
Pasi A. Jänne
, James Chih-Hsin Yang
, et al.
·
New England Journal of Medicine
·
2,261
PDF
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
2021
·
Ferdinandos Skoulidis
, Bob T. Li
, et al.
·
New England Journal of Medicine
·
2,054
PDF
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
2020
·
Michael Wang
, Javier Munoz
, et al.
·
New England Journal of Medicine
·
2,018
PDF
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
2021
·
Toni K. Choueiri
, Thomas Powles
, et al.
·
New England Journal of Medicine
·
1,973
PDF
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
2014
·
Volker Heinemann
, Ludwig Fischer von Weikersthal
, et al.
·
The Lancet Oncology
·
1,892
KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
2020
·
David S. Hong
, Marwan G. Fakih
, et al.
·
New England Journal of Medicine
·
1,881
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
1998
·
Steven A. Rosenberg
, James C. Yang
, et al.
·
Nature Medicine
·
1,853
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
2017
·
Hussein A Tawbi
, Melissa Burgess
, et al.
·
The Lancet Oncology
·
1,579
Criteria for Evaluating Disease Response and Progression in Patients With Multiple Myeloma Treated by High‐dose Therapy and Haemopoietic Stem Cell Transplantation
1998
·
Joan BladÉ
, Diana Samson
, et al.
·
British Journal of Haematology
·
1,564
TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer
2005
·
Roy S. Herbst
, Diane Prager
, et al.
·
Journal of Clinical Oncology
·
1,548
PDF
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
2010
·
Anas Younes
, Nancy L. Bartlett
, et al.
·
New England Journal of Medicine
·
1,446
PDF
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
2017
·
Arjun V Balar
, Daniel Castellano
, et al.
·
The Lancet Oncology
·
1,444
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
2022
·
Javier Cortés
, Sung-Bae Kim
, et al.
·
New England Journal of Medicine
·
1,383
PDF
Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial
2000
·
J.M. Nabholtz
, A. Buzdar
, et al.
·
Journal of Clinical Oncology
·
1,044
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
2016
·
F Stephen Hodi
, Jason Chesney
, et al.
·
The Lancet Oncology
·
1,041
Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study
2000
·
J. Bonneterre
, B. Thürlimann
, et al.
·
Journal of Clinical Oncology
·
888
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab
2007
·
W. De Roock
, H. Piessevaux
, et al.
·
Annals of Oncology
·
880
PDF
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
2019
·
Robert J Motzer
, Brian I Rini
, et al.
·
The Lancet Oncology
·
850
PDF
Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease
2021
·
Eric Jonasch
, Frede Donskov
, et al.
·
New England Journal of Medicine
·
789
PDF
Show more works
View as search
Works count:
2,817
Citation count:
159,400
Year
Topic
Type